Objective: To explore the efficacy and safety of remimazolam combined with propofol for gastroscopy in school-age children.
Methods: A total of 106 children who underwent painless gastroscopy from january to february 2024 were selected, 56 males and 50 females, aged 7-12 years, ASA physical status Ⅰ or Ⅱ. Children were randomly divided into two groups: propofol group (group P) and remimazolam combined with propofol group (group RP), 53 children in each group. After intravenous injection of alfentanil 8 μg/kg, group P was intravenously injected with propofol 2.5 mg/kg, and group RP was intravenously injected with remimazolam 0.183 mg/kg and propofol 1 mg/kg in turn. Gastroscopy was performed when the eyelash reflex disappeared and the modified observer's assessment alertness/sedation scale (MOAA/S) score ≤ 1. The onset time of anesthesia, examination time, and recovery time were recorded. The number of add propofol and successful sedation cases were recorded. Adverse reactions such as respiratory depression, hypotension, bradycardia, injection pain, hiccups, nausea and vomiting were recorded.
Results: Compared with group P, the onset time of anesthesia in group RP was significantly prolonged, and the recovery time was significantly shortened (P < 0.05 ). Compared with group P, the incidence of add propofol, hypotension, respiratory depression and injection pain in group RP were significantly decreased (P < 0.05).
Conclusion: Remazolam combined with propofol for gastroscopy in children can not only ensure the sedative effect, but also reduce the incidence of adverse reactions, stabilize hemodynamic changes and shorten the recovery time. |
